Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c

Avalanche Biotechnologies (NASDAQ: AAVL) reported Q1 EPS of ($0.57), $0.18 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $265 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Largo restructures $82.2M in debt, extending maturity to 2030
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c